Vic W. Schmitt

Corautus Genetics Inc. is a biopharmaceutical company, which manufactures gene therapy products for the treatment of cardiac and vascular disease & peripheral vascular disease. It is located in Atlanta, GA.

Nexell Therapeutics, Inc. develops, manufactures and markets pharmaceutical therapies. Its cell therapy is used for the treatment of genetic blood disorders, autoimmune diseases, cancer, and regenerative medicine applications. The company is headquartered in Irvine, CA.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

Vivaldi Biosciences Inc. develops and markets vaccines. It specializes in developing live attenuated influenza vaccines (LAIVs). The company was founded by Eliott Kieff, Peter Palese, and Adolfo García-Sastre in 2006 and is headquartered in Fort Collins, CO.

Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL.

ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands.

SynGen, Inc. designs and manufactures innovative devices designed for separation and isolation of therapeutic cells. It offers products that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture. The firms products include SynGenX-1000 System, CryoPRO-2 Bag Sets, SynGenX-LAB System, and tube welding workstation. The company was founded by Philip H. Coelho, Gabriel G. Alvarado, and George J. Barry in 1999 and is headquartered in Rancho Cordova, CA

MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX.